Evidence map›Paper›PMID 33615053›Full record

ArticleKidney international reports2021

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor.

Megumi Oshima, Akinori Hara, Tadashi Toyama, Min Jun, Carol Pollock, Meg Jardine, Stephen Harrap, Neil Poulter, Mark E Cooper, Mark Woodward and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Megumi OshimaDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Akinori HaraDepartment of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
Tadashi ToyamaDepartment of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
Min JunDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Carol PollockRenal Department, Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Meg JardineDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Stephen HarrapDepartment of Physiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Neil PoulterInternational Center for Circulatory Health, Imperial College, London, UK.
Mark E CooperDepartiment of Diabetes, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Mark WoodwardDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
John ChalmersDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Vlado PerkovicDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Muh Geot WongDepartment of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Takashi WadaDepartment of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
Kanazawa University · JPUNSW Sydney · AUThe University of Sydney · AUBaker Heart and Diabetes Institute · AUConcord Repatriation General Hospital · AUImperial College London · GBJohns Hopkins University · USThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral circulating markers, including autoantibodies to erythropoietin receptor (anti-EPOR antibodies), have been identified as useful biomarkers in predicting diabetic kidney disease progression. However, a direct comparison of their utility is lacking. We aimed to validate and to compare the prognostic value of anti-EPOR antibodies with that of other known biomarkers, using the ADVANCE trial and its long-term follow-up, ADVANCE-ON, cohorts.

methodsIn this nested case-control study from the ADVANCE trial cohort, we included 165 case participants who had the composite kidney outcome (renal replacement therapy, renal death, or doubling of serum creatinine to ≥200 μmol/l) and 330 matched controls. We compared the associations of baseline plasma levels of anti-EPOR antibodies, tumor necrosis factor receptor (TNFR)-1 and -2, and bone morphogenetic protein (BMP)-7 with kidney outcomes.

resultsCases had higher baseline plasma levels of anti-EPOR antibodies than controls (median 1.7 vs. 0.6 enzyme-linked immunosorbent assay unit,

conclusionAnti-EPOR antibodies provide a promising biomarker, as with TNFR1, TNFR2, and BMP-7, in predicting kidney disease progression in people with type 2 diabetes mellitus.

Indexed as

biomarkerend-stage kidney diseasetype 2 diabetes

Identifiers

PMID33615053
PMCPMC7879109
OpenAlexW3099166545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.